For about a week in 2026, peptide Twitter acted like the war was over. The story, roughly: the FDA was bringing peptides “back,” the bad old days of the do-not-compound list were ending, and everyone could relax. Screenshots flew. Victory laps were taken.
The reality is more interesting than the celebration, and if you’re in Canada, it’s almost entirely beside the point. So let’s actually walk through what happened, what didn’t, and the one fact that the hype skipped right over.
Quick honesty note before we start: this is a plain explainer of a regulatory situation, not legal advice, and everything we sell is strictly research material. We’ll get to exactly what that means at the end, because in Canada it’s the whole story.
The One Thing Everyone Got Wrong
Here’s the headline most people ran with: “the FDA reclassified peptides, so they’re legal now.”
That sentence is wrong twice. “Reclassified” doesn’t mean “legal,” and the thing that happened in the US doesn’t touch Canada at all. Both halves matter, and we’ll take them in order.
What Actually Happened in the US
To follow the news you need one boring piece of vocabulary: the 503A bulks list. In the US, a compounding pharmacy can only build a custom drug from a raw “bulk substance” if that substance is on an approved list. While the FDA evaluates a substance, it sorts it into one of two buckets:
- Category 1, under review, no major safety red flag found yet. Pharmacies can compound it with a prescription while the review continues.
- Category 2, the FDA has flagged a significant safety concern. In practice, no legal compounded supply.
In September 2023, the agency dropped a pile of popular peptides into Category 2, and the gray market has been living in the fallout ever since. Then, on April 15, 2026, the FDA reversed course on a chunk of them, it removed 12 peptides from Category 2.
Here are the 12, because the specifics matter: BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, GHK-Cu, Melanotan II, plus LL-37, Dihexa, DSIP (emideltide), and PEG-MGF. Of those, seven go in front of the FDA’s advisory committee on July 23-24, 2026: BPC-157, KPV, TB-500, and MOTS-c on the 23rd; DSIP, Semax, and Epitalon on the 24th.
Fact check: it’s 12, not “14 of 19.” The viral number was 14, and you’ll still see it everywhere. The official April action was 12. The gap is mostly because CJC-1295 and ipamorelin were quietly pulled off the list back in September 2024, in a separate move, when their nominations were withdrawn, so they get folded into people’s “14” even though they weren’t part of the 2026 news. Small thing, but if you’re going to repeat a number, repeat the right one.
The Catch the Hype Skipped
Now the part nobody screenshotted. Getting pulled out of Category 2 does not make a peptide legal to compound. It just moves it back into the review line.
The law firm Frier Levitt, reading the FDA’s own language, put it bluntly: removal from Category 2 “does not render these bulk drug substances eligible for compounding.” They’re in limbo. To actually become legally compoundable, each one has to clear the July advisory meeting and then survive a formal rulemaking process that, by the FDA’s own estimate, can take more than a year.
So the honest status of, say, BPC-157 in the US right now isn’t “legal again.” It’s “no longer explicitly banned from the review process, pending a vote and then probably a year-plus of paperwork.” That’s a real step, and it genuinely signals the regulators are taking the science more seriously than they were in 2023. But it is not the finish line anyone was celebrating.
The One That Didn’t Get Invited Back: Melanotan II
Worth a quick aside, because it’s the compound everyone asks about every summer. Melanotan II, the tanning peptide that periodically goes viral on TikTok, was removed from Category 2, but it did not get fast-tracked to the July meeting. It’s been parked for a later consultation, currently set for early 2027, alongside injectable GHK-Cu, LL-37, and a couple of others.
Translation: of the buzzy compounds, Melanotan II is the one still sitting in the slow lane. If you were waiting for it to get a clean regulatory blessing this summer, keep waiting.
Now the Part That Actually Matters If You’re Canadian
Here’s where almost every recap falls apart for our audience. All of the above is United States law. The FDA has exactly zero authority over what’s legal in Canada. The reclassification, the July meeting, the 503A list, none of it changes a single Canadian rule.
And Canada’s rules are their own thing. In April 2026, Health Canada put out a public advisory that didn’t mince words. Its position: “in Canada, peptides are generally regulated as prescription drugs.” Authorized ones need a DIN (a drug identification number) and a practitioner. Unauthorized versions, in Health Canada’s own framing, are “illegal in Canada.”
The advisory went further, straight at the label you’ve seen on every research vial: a “research use only, not for human consumption” tag, it said, “does not make these products legal or exempt from regulatory requirements.” Health Canada explicitly tells consumers not to inject products carrying that label.
So what does that actually mean? It means the honest answer to “are peptides legal in Canada” is: as drugs for human use, no, they’re unapproved. The “research use only” framing isn’t a loophole that makes human use legal. It’s a description of what these compounds actually are: laboratory research materials, sold for laboratory research, with no therapeutic claims attached. The line that draws regulatory heat is selling unapproved products for human consumption or making medical claims about them. Genuine research supply, clearly labeled and claim-free, is the lane that exists.
One myth to kill while we’re here: you’ll sometimes see “CASL” cited in these conversations as if it governs peptide labeling. It doesn’t. CASL is Canada’s anti-spam law, it’s about marketing emails and consent. The labeling rules live under the Food and Drugs Act. Different law, different universe.
So Where Does That Leave You?
If you’re a Canadian buyer trying to make sense of the headlines, here’s the clean version:
The US is slowly, cautiously reopening the door to compounded peptides, but the door isn’t open yet, and it’s a US door. In Canada, these remain unapproved drugs, and the only legitimate framing is research use: material sold for the lab, not for the body, with no medical claims.
That sounds restrictive, and it is. But it also clarifies what actually matters when you’re sourcing research peptides, and it’s not the FDA’s category list. It’s whether the vial contains what the label says. The entire gray market runs on trust, and “trust me” is doing a lot of work out there. Underdosed, mislabeled, and contaminated material is the norm, not the exception, which is exactly why everything we carry ships with third-party Janoshik lab testing: purity, identity, sterility, posted, per compound. The regulatory weather will keep changing. What’s in the bottle is the part you can actually verify.
What to Watch Next
- July 23-24, 2026: the FDA advisory meeting on the seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon). The vote is advisory only, it doesn’t change the law by itself.
- After that: formal rulemaking, which can run a year or more before anything is actually compoundable in the US.
- Early 2027: the deferred batch, including Melanotan II and injectable GHK-Cu, gets its own review.
- In Canada: likely nothing changes from any of this. Health Canada moves on its own timeline and its own logic.
If you want the deeper science on the compounds in the spotlight, our BPC-157 vs TB-500 breakdown covers the two headliners, and if it’s the GLP-1 weight-loss side of the peptide world you’re curious about, we did the honest version of that in peptides for weight loss.
The short version of the whole saga: the US took a real but small step, the internet oversold it, and Canada’s answer didn’t move an inch. Knowing the difference is worth more than any screenshot.
This article is a plain-English explainer of a developing regulatory situation, for educational purposes only. It is not legal or medical advice. Regulatory status changes; verify current rules with primary sources before relying on anything here. All Peptigo products are sold strictly for laboratory and research use only, not for human or veterinary use. Peptigo does not make medical claims.
Key sources: FDA bulk-substances notices (April 2026); Frier Levitt and FDA Law Blog analyses of the April 15, 2026 Category 2 removals; Health Canada public advisory (April 9, 2026).